The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information:

Study Name on (link is external)
A Phase 1 Study of VX-522 in Participants With Cystic Fibrosis (CF)
Study DrugVX-522
Type of Study DrugmRNA therapy
Study TitleA Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy
Study Phase1
Study SponsorVertex

Link on (link is external)

Participating ECFS-CTN sitesPlease contact for most recent sitelist
AgeAdult patients